Sex and gender differences substantially influence Alzheimer's disease pathology, progression, and treatment response, yet remain underrepresented in research design and clinical trials. The Sex | Gender in Neurodegeneration Consortium addresses this evidence gap by systematizing investigation of biological sex, gender identity, and social determinants in neurodegeneration, with implications for personalized prevention and intervention strategies.
Key Points
- Sex differences drive distinct Alzheimer's pathology and disease trajectories.
- Gender and social factors modulate neurodegeneration risk and treatment outcomes.
- Consortium standardizes sex-disaggregated research to advance precision neurology.
Longevity Analysis
Alzheimer's represents a failure of multiple coordinated systems—neuronal regeneration, metabolic efficiency, hormonal signaling, and stress resilience all deteriorate in tandem. Current research has largely treated the disease as biologically uniform, obscuring the fact that sex-dependent variations in hormone metabolism, immune defense, and neuroinflammatory responses create different vulnerabilities and different windows for intervention. A sex-informed framework for understanding neurodegeneration is not academic refinement; it directly affects which prevention strategies work for which populations, which biomarkers reliably predict decline, and when interventions should begin. This work exposes a blind spot in how we decode the body's signals during cognitive aging.
Original published by Nature Aging, by Caitlin P. McHugh.